AstraZeneca's Saphnelo approved in Japan for lupus treatment

AstraZeneca's Saphnelo (anifrolumab) has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of adult patients with systemic lupus erythematosus (SLE) who have an insufficient response to currently available therapies.

The Japanese approval is based on efficacy and safety data from the Saphnelo clinical development program, including the Phase III TULIP trials and the Phase II MUSE trial. These studies showed that Saphnelo reduced overall disease activity across organ systems, including skin and joints, more effectively than placebo. Patients treated with Saphnelo also achieved a sustained reduction in the use of oral corticosteroids.

This marks the first regulatory approval in Japan for a type I interferon (IFN) receptor antagonist. Type I IFN is known to play a central role in the pathophysiology of lupus, and increased type I IFN signaling has been associated with higher disease activity and severity.

SLE is a serious autoimmune disease that can affect any organ in the body, often leading to inadequate disease control, long-term organ damage, and a reduced quality of life. Japan has approximately 60,000 registered SLE patients, the majority of whom are women. The disease is designated as intractable in Japan, encouraging research into treatments for rare conditions with limited therapeutic options.